CONCORD, Mass. & MELBOURNE, Australia--(BUSINESS WIRE)--ClearB Therapeutics, Inc., a company developing a therapeutic vaccine designed to drive functional cure of hepatitis B, announced today that its ...

CUPERTINO, Calif., Oct. 21, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that the results from the recently completed Phase 2a study of DUR-928 in patients with alcoholic ...

The included AIH cohort consisted of 145 males and 504 (78%) females with a mean age at diagnosis of 48 years (s.d.±18). The median revised IAIHG diagnostic score was 18 (interquartile range: 15–20).

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its participation in an industry panel discussion at the Canaccord Adams' ...

SAN FRANCISCO, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that three abstracts highlighting data from its hepatitis B clinical program and one health ...

CONCORD, Mass., April 25, 2025--(BUSINESS WIRE)--ClearB Therapeutics, Inc., a company developing therapeutic vaccines designed to drive a functional cure for Hepatitis B, announced today that an ...

A 59-year-old normotensive male was referred from a local optometrist via diabetic screening pathway with ‘preproliferative’ changes in both fundi. Patient had past medical history of schizophrenia, ...

ClearB Therapeutics, Inc., a company developing therapeutic vaccines designed to drive a functional cure for Hepatitis B, announced today that an abstract will be presented as a poster at the European ...